CBIO Earnings & Financial Statements
Crescent Biopharma, Inc.
$13.18
-$0.31(-2.30%)
34
Overall
40
Value
36
Tech
28
Quality
Market Cap
$501.07M
Volume
13.81K
52W Range
$8.72 - $27.41
Target Price
$31.33
CBIO earnings and financial statements: Crescent Biopharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CBIO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $10.84M | - | $10.0K | $75.0K | $1.16M |
| Operating income | -$152.63M | -$17.19M | -$39.28M | -$47.40M | -$63.45M |
| EBITDA | -$149.46M | -$17.02M | -$35.89M | -$47.20M | -$63.18M |
| Net income | -$153.94M | -$17.87M | -$36.90M | -$46.69M | -$63.43M |
| EPS (diluted) | - | $-59.00 | $-58.00 | $-89.00 | $-123.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $240.29M | $35.62M | $45.32M | $51.81M | $94.35M |
| Total liabilities | $37.28M | $47.10M | $6.90M | $8.88M | $12.74M |
| Shareholders’ equity | $203.01M | -$15.48M | $38.41M | $42.93M | $81.60M |
| Cash and equivalents | $213.19M | $34.77M | $41.79M | $47.87M | $90.25M |
| Long-term debt | $1.21M | $37.48M | $66.8K | - | $918.6K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$71.53M | -$6.27M | -$34.88M | -$46.46M | -$57.49M |
| Capital expenditure | -$72.92M | - | -$21.4K | -$84.2K | -$14.9K |
| Free cash flow | -$144.45M | -$6.27M | -$34.90M | -$46.54M | -$57.50M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CBIO | $13.18 | -2.3% | 13.81K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Crescent Biopharma, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW